A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy

Tsung I. Hsu, Ying Jung Chen, Chia Yang Hung, Yi Chang Wang, Sin Jin Lin, Wu Chou Su, Ming Derg Lai, Sang Yong Kim, Qiang Wang, Keduo Qian, Masuo Goto, Yu Zhao, Yoshiki Kashiwada, Kuo Hsiung Lee, Wen Chang Chang, Jan Jong Hung

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Herein, we evaluated the anti-cancer effect and molecular mechanisms of a novel betulinic acid (BA) derivative, SYK023, by using two mouse models of lung cancer driven by KrasG12D or EGFRL858R. We found that SYK023 inhibits lung tumor proliferation, without side effects in vivo or cytotoxicity in primary lung cells in vitro. SYK023 triggered endoplasmic reticulum (ER) stress. Blockage of ER stress in SYK023-treated cells inhibited SYK023-induced apoptosis. In addition, we found that the expression of cell cycle-related genes, including cyclin A2, B1, D3, CDC25a, and CDC25b decreased but, while those of p15INK4b, p16INK4a, and p21CIP1 increased following SYK023 treatment. Finally, low doses of SYK023 significantly decreased lung cancer metastasis in vitro and in vivo. Expression of several genes related to cell migration, including synaptopodin, were downregulated by SYK023, thereby impairing F-actin polymerization and metastasis. Therefore, SYK023 may be a potentially therapeutic treatment for metastatic lung cancer.

Original languageEnglish
Pages (from-to)13671-13687
Number of pages17
JournalOncotarget
Volume6
Issue number15
Publication statusPublished - 2015

Fingerprint

Lung Neoplasms
Endoplasmic Reticulum Stress
Cyclin A2
Growth
Neoplasm Metastasis
Cyclin B1
cdc Genes
Neoplasms
Lung
Polymerization
Cell Movement
Actins
Down-Regulation
Apoptosis
Gene Expression
betulinic acid
In Vitro Techniques
Therapeutics

Keywords

  • ER stress
  • Metastasis
  • syk023
  • Synaptopodin

ASJC Scopus subject areas

  • Oncology

Cite this

Hsu, T. I., Chen, Y. J., Hung, C. Y., Wang, Y. C., Lin, S. J., Su, W. C., ... Hung, J. J. (2015). A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy. Oncotarget, 6(15), 13671-13687.

A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy. / Hsu, Tsung I.; Chen, Ying Jung; Hung, Chia Yang; Wang, Yi Chang; Lin, Sin Jin; Su, Wu Chou; Lai, Ming Derg; Kim, Sang Yong; Wang, Qiang; Qian, Keduo; Goto, Masuo; Zhao, Yu; Kashiwada, Yoshiki; Lee, Kuo Hsiung; Chang, Wen Chang; Hung, Jan Jong.

In: Oncotarget, Vol. 6, No. 15, 2015, p. 13671-13687.

Research output: Contribution to journalArticle

Hsu, TI, Chen, YJ, Hung, CY, Wang, YC, Lin, SJ, Su, WC, Lai, MD, Kim, SY, Wang, Q, Qian, K, Goto, M, Zhao, Y, Kashiwada, Y, Lee, KH, Chang, WC & Hung, JJ 2015, 'A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy', Oncotarget, vol. 6, no. 15, pp. 13671-13687.
Hsu TI, Chen YJ, Hung CY, Wang YC, Lin SJ, Su WC et al. A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy. Oncotarget. 2015;6(15):13671-13687.
Hsu, Tsung I. ; Chen, Ying Jung ; Hung, Chia Yang ; Wang, Yi Chang ; Lin, Sin Jin ; Su, Wu Chou ; Lai, Ming Derg ; Kim, Sang Yong ; Wang, Qiang ; Qian, Keduo ; Goto, Masuo ; Zhao, Yu ; Kashiwada, Yoshiki ; Lee, Kuo Hsiung ; Chang, Wen Chang ; Hung, Jan Jong. / A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy. In: Oncotarget. 2015 ; Vol. 6, No. 15. pp. 13671-13687.
@article{b9a613a6d3604a9dbad6ad28bd97c761,
title = "A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy",
abstract = "Herein, we evaluated the anti-cancer effect and molecular mechanisms of a novel betulinic acid (BA) derivative, SYK023, by using two mouse models of lung cancer driven by KrasG12D or EGFRL858R. We found that SYK023 inhibits lung tumor proliferation, without side effects in vivo or cytotoxicity in primary lung cells in vitro. SYK023 triggered endoplasmic reticulum (ER) stress. Blockage of ER stress in SYK023-treated cells inhibited SYK023-induced apoptosis. In addition, we found that the expression of cell cycle-related genes, including cyclin A2, B1, D3, CDC25a, and CDC25b decreased but, while those of p15INK4b, p16INK4a, and p21CIP1 increased following SYK023 treatment. Finally, low doses of SYK023 significantly decreased lung cancer metastasis in vitro and in vivo. Expression of several genes related to cell migration, including synaptopodin, were downregulated by SYK023, thereby impairing F-actin polymerization and metastasis. Therefore, SYK023 may be a potentially therapeutic treatment for metastatic lung cancer.",
keywords = "ER stress, Metastasis, syk023, Synaptopodin",
author = "Hsu, {Tsung I.} and Chen, {Ying Jung} and Hung, {Chia Yang} and Wang, {Yi Chang} and Lin, {Sin Jin} and Su, {Wu Chou} and Lai, {Ming Derg} and Kim, {Sang Yong} and Qiang Wang and Keduo Qian and Masuo Goto and Yu Zhao and Yoshiki Kashiwada and Lee, {Kuo Hsiung} and Chang, {Wen Chang} and Hung, {Jan Jong}",
year = "2015",
language = "English",
volume = "6",
pages = "13671--13687",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "15",

}

TY - JOUR

T1 - A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy

AU - Hsu, Tsung I.

AU - Chen, Ying Jung

AU - Hung, Chia Yang

AU - Wang, Yi Chang

AU - Lin, Sin Jin

AU - Su, Wu Chou

AU - Lai, Ming Derg

AU - Kim, Sang Yong

AU - Wang, Qiang

AU - Qian, Keduo

AU - Goto, Masuo

AU - Zhao, Yu

AU - Kashiwada, Yoshiki

AU - Lee, Kuo Hsiung

AU - Chang, Wen Chang

AU - Hung, Jan Jong

PY - 2015

Y1 - 2015

N2 - Herein, we evaluated the anti-cancer effect and molecular mechanisms of a novel betulinic acid (BA) derivative, SYK023, by using two mouse models of lung cancer driven by KrasG12D or EGFRL858R. We found that SYK023 inhibits lung tumor proliferation, without side effects in vivo or cytotoxicity in primary lung cells in vitro. SYK023 triggered endoplasmic reticulum (ER) stress. Blockage of ER stress in SYK023-treated cells inhibited SYK023-induced apoptosis. In addition, we found that the expression of cell cycle-related genes, including cyclin A2, B1, D3, CDC25a, and CDC25b decreased but, while those of p15INK4b, p16INK4a, and p21CIP1 increased following SYK023 treatment. Finally, low doses of SYK023 significantly decreased lung cancer metastasis in vitro and in vivo. Expression of several genes related to cell migration, including synaptopodin, were downregulated by SYK023, thereby impairing F-actin polymerization and metastasis. Therefore, SYK023 may be a potentially therapeutic treatment for metastatic lung cancer.

AB - Herein, we evaluated the anti-cancer effect and molecular mechanisms of a novel betulinic acid (BA) derivative, SYK023, by using two mouse models of lung cancer driven by KrasG12D or EGFRL858R. We found that SYK023 inhibits lung tumor proliferation, without side effects in vivo or cytotoxicity in primary lung cells in vitro. SYK023 triggered endoplasmic reticulum (ER) stress. Blockage of ER stress in SYK023-treated cells inhibited SYK023-induced apoptosis. In addition, we found that the expression of cell cycle-related genes, including cyclin A2, B1, D3, CDC25a, and CDC25b decreased but, while those of p15INK4b, p16INK4a, and p21CIP1 increased following SYK023 treatment. Finally, low doses of SYK023 significantly decreased lung cancer metastasis in vitro and in vivo. Expression of several genes related to cell migration, including synaptopodin, were downregulated by SYK023, thereby impairing F-actin polymerization and metastasis. Therefore, SYK023 may be a potentially therapeutic treatment for metastatic lung cancer.

KW - ER stress

KW - Metastasis

KW - syk023

KW - Synaptopodin

UR - http://www.scopus.com/inward/record.url?scp=84931097744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931097744&partnerID=8YFLogxK

M3 - Article

C2 - 25909174

AN - SCOPUS:84931097744

VL - 6

SP - 13671

EP - 13687

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 15

ER -